melsm,oncology,MedEd,MedTwitter

Mashup Score: 3

FDA Grants Breakthrough Therapy Designation to RP1 Plus Nivolumab in Advanced Melanoma - 11 hour(s) ago

RP1 plus nivolumab received breakthrough therapy designation from the FDA for the treatment of patients with PD-1 inhibitor–exposed advanced melanoma.

Source: www.onclive.com

Categories: General Medicine News, Oncologists1

Tweet Tweets with this article
- OncLive
  
  FDA Grants Breakthrough Therapy Designation to RP1 Plus Nivolumab in Advanced Melanoma @US_FDA #melsm #oncology #MedEd #MedTwitter https://t.co/xeNwrVNxlm